Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperpigmentation Clear all
Completed Phase 4 Interventional

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

NCT00469183
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging

NCT05423873
View directory record Official record
Conditions
Hyperpigmentation, Photodamaged Skin, Wrinkle, Fine Lines
Interventions
Gentle Cleansing Lotion, Revision Skincare
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Solana Beach, California • Greenwood Village, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

RASopathy Biorepository

NCT04395495
View directory record Official record
Conditions
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2065
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 6, 2026, 1:12 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of an Herbal-Based De-Pigmenting System

NCT02138539
View directory record Official record
Conditions
Melasma, Hyperpigmentation
Interventions
Herbal depigmenting agent (Epionce), Hydroquinone
Other · Drug
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 6, 2026, 1:12 AM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

NCT03402893
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
ONEXTON Topical Gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging

NCT04137263
View directory record Official record
Conditions
Melasma
Interventions
DOSE formulation
Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 6, 2026, 1:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00239135
View directory record Official record
Conditions
Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 6, 2026, 1:12 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lutronic PicoPlus Exploratory Clinical Trial

NCT03415685
View directory record Official record
Conditions
Tattoo; Pigmentation, Melasma, Benign Pigmented Lesion
Interventions
PicoPlus laser system
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Newport Beach, California • Elmhurst, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 6, 2026, 1:12 AM EDT
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Polypodium Leucotomos for Melasma

NCT01162850
View directory record Official record
Conditions
Melasma
Interventions
Polypodium Leucotomos, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Sep 6, 2026, 1:12 AM EDT
Not listed Phase 4 Interventional

Efficacy & Safety of Clindamycin and Tretinoin in Acne

NCT01111994
View directory record Official record
Conditions
Acne
Interventions
Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Mitchellville, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2010 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin

NCT00641420
View directory record Official record
Conditions
Acne Scarring
Interventions
Fractionated Laser Resurfacing
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center 2-Arm Study for Lentigines on the Hands

NCT02763072
View directory record Official record
Conditions
Lentigines
Interventions
Enlighten Laser, Excel V Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
30 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

NCT05704114
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Erythema, Skin Scarring
Interventions
Tazarotene 0.045% Lotion
Drug
Lead sponsor
Dr. Emmy Graber
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 6, 2026, 1:12 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Not applicable Interventional Results available

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

NCT01491620
View directory record Official record
Conditions
Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
Interventions
532 nm KTP laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 6, 2026, 1:12 AM EDT
Withdrawn Phase 2 Interventional

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

NCT06473974
View directory record Official record
Conditions
Facial Hyperpigmentation
Interventions
Test cosmetic product
Drug
Lead sponsor
Kayuraeffect, LLP
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 6, 2026, 1:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

NCT06415435
View directory record Official record
Conditions
Melasma
Interventions
Radiofrequency Microneedling
Device
Lead sponsor
Benev Company, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
La Jolla, California • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 6, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

NCT06940895
View directory record Official record
Conditions
Acanthosis Nigricans
Interventions
Sirolimus 0.2%
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 6, 2026, 1:12 AM EDT